



## Post Authorisation Assessments

### Prednisolone Tablets B.P. (Vet) 1 mg Vm 61300/5003

23 April 2026	Change of marketing authorisation holder name from Millpledge Europe BVBA to Millpledge Europe BV.
27 October 2025	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex.
28 August 2025	Change of legal entity of the Marketing Authorisation Holder from Millpledge Ltd, Whinleys Estate, Clarbrough, Retford, Nottinghamshire, DN22 9NA to Millpledge Europe BVBA, 38 Verrekijker, 8750 Wingene, Belgium
28 April 2025	Replacement of a test procedure for the active substance.
18 May 2024	Reduction in the testing frequency of an analysis, from routine testing to skip or periodic testing.
27 June 2023	Change in the shelf-life or storage conditions of the finished product: - Extension of the shelf life of the finished product - As packaged for sale.
22 December 2022	Addition of a microbiological testing site.
07 December 2022	Change in the name or address or contact details of a qualified person for pharmacovigilance.
19 August 2022	Change in batch size of the finished product. Replacement quality control testing site for the finished product. Additional batch release site for the finished product.
18 May 2022	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
01 April 2021	Change in storage conditions of the finished product.
11 March 2021	Addition of a new specification parameter to the specification with its corresponding test method of the finished product. Deletion of a non-significant specification parameter of the finished product. Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
03 November 2020	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS. Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
22 January 2020	Update of ingredients of ruminant origin.
14 January 2020	Change in the safety database of an existing

	pharmacovigilance system as described in the DDPS.
24 December 2019	<p>Addition of a new specification parameter to the specification with its corresponding test method of the finished product.</p> <p>Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur for the finished product.</p> <p>Addition of a site where batch control/testing takes place.</p> <p>Deletion of manufacturing site for an active substance.</p> <p>Submission of a new Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.</p>
22 August 2018	<p>Changes in the qualitative and quantitative composition of the immediate packaging of the finished product for solid pharmaceutical forms.</p> <p>Deletion of a manufacturing site, packaging site and testing.</p>
11 June 2018	Addition of a site where batch control/testing takes place.
01 September 2011	Addition of a tested of final dosage form (from outside of EU).
01 September 2011	Variation to replace an importer of dosage (from outside of EU).
05 November 2008	Change to test procedures for the finished product.
26 June 2008	Variation to bring the SPC/ Labelling in line with the Veterinary Regulations, 2005. Transfer of legal category from POM to POM-V.
16 June 2008	Extension of finished product shelf life.
16 June 2008	Addition of a manufacturer/assembler for dosage form.
07 April 2008	Addition of different bossing on tablets.
07 August 2007	Renewal.
19 October 2005	Addition of an active substance manufacturer.
22 August 2003	Renewal.
20 October 2002	Change to FPS.
10 February 1998	Change to finished product formulation.